J. Kevin Buchi - 11 Aug 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Reporting relationship: Director
Issuer ticker: AMRX
Reported as of: 11 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Aug 2026, 16:21:02 UTC
Prior SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Denis Butkovic, Attorney-in-Fact

Key filing fact

J. Kevin Buchi filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 13 Aug 2026.

Key facts

This page summarizes J. Kevin Buchi's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 16:21.

Change

Previous filing in this sequence was filed on 30 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001209726 Primary reporting owner

BUCHI J KEVIN

Relationship: Director
Address: C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: -168,573
Change %: -64%
Price: $17.18^*
Shares after: 93,499
Date: 11 Aug 2026
Ownership: By Trust
Footnotes: F1

AMRX holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 75,077
Date: 11 Aug 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.